摘要
文章总结导师侯仰韶主任医师治疗肺癌患者表皮生长因子受体-酪氨酸激酶抑制剂(Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors,EGFR-TKIs)相关性皮疹经验。肺癌是世界上常见恶性肿瘤之一,我国肺癌患者的发病率和病死率逐年上升。随着肺癌治疗药物不断的更新换代,EGFR-TKIs已成为表皮生长因子受体(Epidermal Growth Factor Receptor,EGFR)基因突变肺癌患者的常规治疗手段,在临床中广泛使用。EGFR-TKIs与传统化疗药物相比,具有更长的生存期、更少的不良反应等优势。但伴随EGFR-TKIs治疗出现的皮疹、瘙痒等不良反应,仍影响着患者的生活质量和服药依从性。中药在肺癌治疗中有独特的优势,能够缓解放化疗、靶向治疗、免疫治疗的不良反应,改善患者症状,延长生存周期。侯仰韶主任医师认为,肺癌患者热毒蕴结于肺,素体亏虚,EGFR-TKIs治疗后,药物毒邪伤及肺脾,湿热内生,透表可发为皮疹。EGFR-TKIs治疗后的肺癌患者主要证型可归属于湿热内蕴兼肺脾气虚证。因此,侯仰韶主任医师以清热解毒、燥湿止痒、健脾益肺为治则,自拟“扶正解毒抑瘤方”,应用于临床。此外,导师在肺癌的治疗中,重视“同病类证类治”的治疗理念,临床中根据患者症状,在自拟方扶正解毒抑瘤方的基础上进行加减化裁,取得良好治疗效果。文章就导师侯仰韶主任医师临床治疗EGFR-TKIs相关性皮疹经验做简要阐述,并附病例1则,予以佐证。
This paper summarizes the experience of the Chief Physician HOU Yangshao in treating skin rash reduced by epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in patients with lung cancer.Lung cancer is one of the most common malignant tumors in the world.The incidence and mortality of lung cancer patients in China are increasing year by year.With the continuous updating of lung cancer treatment drugs,EGFR-TKIs has become a routine treatment for lung cancer patients with epidermal growth factor receptor(EGFR)gene mutation,and it is widely used in clinical practice.Compared with traditional chemotherapy drugs,EGFR-TKIs has the advantages of longer survival and fewer adverse reactions.However,the adverse reactions such as rash and pruritus accompanying EGFR-TKIs treatment still affect patients’quality of life and medication compliance.Traditional Chinese medicine has unique advantages in the treatment of lung cancer,which can alleviate the adverse reactions of radiotherapy and chemotherapy,targeted treatment and immunotherapy,relieve the symptoms of patients and prolong the survival cycle.Chief Physician HOU Yangshao believes that lung cancer patients suffer from heat toxin accumulation in the lung and body deficiency,after the treatment of EGFR-TKIs,the lung and spleen are injured by the toxic pathogens,and the dampness and heat are endogenous,which can cause skin rash through the surface.The main syndrome type of lung cancer patients after EGFR-TKIs treatment can be attributed to damp-heat syndrome combined with lung Qi(气)deficiency.Therefore,Chief Physician HOU Yangshao advocates the treatment principle of clearing heat and detoxification,drying dampness and relieving itching,invigorating spleen and tonifying lung,and designs Fuzheng Jiedu Yiliu formula(扶正解毒抑瘤方),which is applied in clinical practice.In addition,in the treatment of lung cancer,the mentor attaches importance to the treatment concept of“treating the same disease with the same symptoms by the same treatment metho
作者
郭哲
孙先超
侯仰韶
GUO Zhe;SUN Xianchao;HOU Yangshao
出处
《中医临床研究》
2024年第6期81-84,共4页
Clinical Journal Of Chinese Medicine
关键词
肺癌
表皮生长因子受体-酪氨酸激酶抑制剂
皮疹
扶正解毒抑瘤方
同病类证类治
Lung cancer
Epidermal growth factor receptor-tyrosine kinase inhibitor
Rash
Fuzheng Jiedu Yiliu formula
Treating the same disease with the same symptoms by the same treatment method
